^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KMT2D underexpression

    i
    Other names: KMT2D, Lysine Methyltransferase 2D, Histone-Lysine N-Methyltransferase 2D, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 2, Lysine (K)-Specific Methyltransferase 2D, Trinucleotide Repeat Containing 21, Lysine N-Methyltransferase 2D, ALL1-Related Protein, MLL2, MLL4, ALR, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Histone-Lysine N-Methyltransferase MLL2, Truncated Lysine Methyltransferase 2D, Kabuki Mental Retardation Syndrome, Kabuki Make-Up Syndrome, CAGL114, KABUK1, TNRC21, AAD10
    Entrez ID:
    8085
    Related biomarkers:
    Mutation
    Others
    over2years
    TUMOR CELL INTRINSIC LOSS OF KMT2D REMODELS PANCREATIC TUMOR MICROENVIRONMENT AND ACTIVATES A NON-CANONICAL ACTIVIN A PATHWAY (DDW 2022)
    Mechanistically, we found that KMT2D loss in PDAC cells induces the expression and secretion of activin A, a member of the TGF-β superfamily, and subsequently activates a non-canonical p38 pathway. These Results suggest that KMT2D is a critical tumor suppressor, partly by promoting an immunogenic and tumor-suppressive TME, and the activin A-p38 pathway may serve as a potential therapeutic target for PDAC.
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • KMT2D (Lysine Methyltransferase 2D) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    KRAS mutation • KRAS G12D • KMT2D mutation • KRAS G12 • KMT2D underexpression